Structure-Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off-Target Effects. [PDF]
Passeri D +11 more
europepmc +1 more source
Unveiling a novel macrophage-driven mechanism for obeticholic acid-induced liver injury in cholestatic: targeting NLRP12<sup>Arg185</sup> fuels Relb-TNFSF14-mediated ductular reaction. [PDF]
Wang J +10 more
europepmc +1 more source
Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. [PDF]
Jamal F +11 more
europepmc +1 more source
Hepatic angiosarcoma in a patient treated with obeticholic acid for primary biliary cholangitis. [PDF]
Arif AA +4 more
europepmc +1 more source
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world. [PDF]
Terracciani F +104 more
europepmc +1 more source
Tailoring obeticholic acid activity by iridium(III) complex conjugation to develop a farnesoid X receptor probe. [PDF]
Niu D +8 more
europepmc +1 more source
Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy. [PDF]
Wang Y +6 more
europepmc +1 more source
Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design. [PDF]
Brookhart MA +19 more
europepmc +1 more source
Obeticholic Acid Improves Cholestasis, Liver Fibrosis, and Liver Function in Patients with Primary Biliary Cholangitis with Inadequate Response to Ursodeoxycholic Acid. [PDF]
Buechter M +4 more
europepmc +1 more source
COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls. [PDF]
Kowdley KV +23 more
europepmc +1 more source

